Apimeds Pharmaceuticals US, Inc. completed an initial public offering in May 2025, raising $13.5 million to support clinical development activities.

• The company completed an initial public offering on May 12, 2025, raising $13.5 million for clinical development of its lead drug candidate, Apitox [N1].

The company’s lead product candidate, Apitox, targets a significant unmet medical need in knee osteoarthritis pain and inflammation. The successful completion of an IPO raising $13.5 million provides capital to advance clinical development. The merger with MindWave Innovations Inc. diversifies the company’s asset base by adding digital assets, which have contributed realized gains in 2025. If clinical development progresses successfully, the company could establish a foothold in the biopharmaceutical market for pain management. The company’s licensing agreements and intellectual property arrangements provide a foundation for commercialization in the United States.

Apimeds Pharmaceuticals US, Inc. is a development-stage company with no current revenue from its biopharmaceutical operations and significant net losses. The expiration of patents related to Apitox without plans for renewal may expose the company to competitive risks. The company’s liquidity is constrained, with a cash ratio of 0.34 and recurring negative cash flows raising substantial doubt about its ability to continue as a going concern. The digital asset segment introduces volatility and does not offset the operational risks of the biopharmaceutical business. The company’s reliance on related party promissory notes and convertible notes indicates ongoing financing needs. Clinical development risks, regulatory hurdles, and market acceptance remain significant challenges.

Apimeds Pharmaceuticals US, Inc. is in the early stages of developing a novel biopharmaceutical product, Apitox, based on honeybee venom for knee osteoarthritis pain. The company holds sublicensable licenses and intellectual property rights related to Apitox, including agreements with Apimeds Korea and Dr. Christopher Kim. However, the company’s patents expired in 2023 and it does not intend to renew or apply for new patents, which may limit exclusivity. The company’s moat is primarily based on its proprietary formulation and clinical development progress rather than patent protection. The recent merger with MindWave Innovations Inc. adds a digital asset segment, which is unrelated to the core biopharmaceutical business and does not contribute to a competitive moat in the pharmaceutical sector.

• Going Concern Risk: The company has recurring operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Patent Expiration: Patents related to Apitox expired in 2023, and the company does not intend to renew or apply for new patents, potentially limiting exclusivity and competitive advantage.
• No Revenue from Biopharmaceutical Operations: The company has not generated revenue from its biopharmaceutical segment, increasing reliance on financing and digital asset gains.
• Liquidity Constraints: Cash and cash equivalents are limited relative to current liabilities, with a cash ratio of 0.34, indicating potential liquidity challenges.
• Digital Asset Volatility: The digital asset segment introduces exposure to cryptocurrency market volatility, which may impact financial results and operational stability.

• Apimeds Pharmaceuticals US, Inc. is a development-stage biopharmaceutical company incorporated in Delaware as a C-Corporation focused on developing Apitox, a purified honeybee venom-based drug for acute pain and inflammation associated with knee osteoarthritis.
• The company operates its biopharmaceutical business through a wholly owned subsidiary, Lokahi Therapeutics Inc., and acquired MindWave Innovations Inc. on December 1, 2025, which operates the digital asset segment.
• The digital asset segment includes holdings of Bitcoin (BTC), Tether (USDT), and MindWaveDAO NILA tokens (NILA Tokens).
• The company completed a merger with MindWave Innovations Inc. on December 1, 2025, acquiring digital assets and related operations.
• Apimeds Pharmaceuticals US, Inc. completed an initial public offering (IPO) on May 12, 2025, raising $13.5 million for clinical development [N1].
• As of December 31, 2025, the company had cash and cash equivalents of $1,636,655, short-term investments of $2,000,000, and total current assets of $13,983,859.
• The company had current liabilities of $10,706,455 as of December 31, 2025, resulting in a current ratio of 1.31 and a cash ratio of 0.34.
• The company reported a net loss of $6,001,137 for the year ended December 31, 2025, with basic and diluted earnings per share of -$0.55.
• Operating expenses for 2025 totaled $11,912,562, including research and development expenses of $1,632,581 and general and administrative expenses of $10,279,981.
• The company has not generated revenue from its biopharmaceutical operations as of the latest reporting period.
• The digital asset segment reported realized gains on sale of digital assets totaling approximately $4.2 million in 2025.
• The company has multiple promissory notes and convertible notes payable to related parties, including Inscobee, Inc. and Apimeds Korea, with terms linked to equity financing events.
• The company has an operating lease for office space in San Diego, California, with a term from January 1, 2026, to December 31, 2028, and a lease liability of $169,032 as of December 31, 2025.
• The company’s audit committee was established on February 7, 2025, and oversees related party transactions and audit services.
• The company’s consolidated financial statements have been prepared assuming it will continue as a going concern, but recurring losses and negative cash flows raise substantial doubt about its ability to continue without additional financing [S1].